Loading...
Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms
Morgan, Celia J. A. Page, Emma Schaefer, Carola Chatten, Katharine Manocha, Amod Gulati, Sumit Curran, H. Valerie Brandner, Brigitta Leweke, F. Markus
Morgan, Celia J. A.
Page, Emma
Schaefer, Carola
Chatten, Katharine
Manocha, Amod
Gulati, Sumit
Curran, H. Valerie
Brandner, Brigitta
Leweke, F. Markus
Abstract
Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ9-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.
Keywords
Date
2013
Type
Journal article
Journal
British Journal of Psychiatry
Book
Volume
202
Issue
5
Page Range
381-382
Article Number
ACU Department
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled